<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>

Investors

HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. HLS Therapeutics listed publicly on the TSXV in March 2018 by way of a reverse takeover of Automodular Corporation.

EVENTS
Wednesday, May 16, 2018
8:30am - 9:30am EDT


View All

SHARE PRICE
CDXHLS
INVESTOR PRESENTATION

The information contained on the Investor Relations section of this website was accurate at the time of posting, but may be superseded by subsequent disclosures. Please check the date of the material posted.


PRESS RELEASES
Jun 25, 2018

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario. A...

Jun 15, 2018

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces details of its upcoming Annual Meeting of Shareholders. Date: Friday June 22, 2018 Time: 10:00 a.m. ET Location: Blake, Cassels...

May 30, 2018

HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it has entered into an automatic share purchase plan (the "ASPP") with a designated broker in order to facilitate...


Read More